{"id":"ambrisentan-plus-spironolactone","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nasal congestion"}]},"_chembl":{"chemblId":"CHEMBL1111","moleculeType":"Small molecule","molecularWeight":"378.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ambrisentan is an endothelin receptor antagonist (ERA) that selectively blocks endothelin-1 signaling in pulmonary vasculature, causing vasodilation and reducing right ventricular afterload. Spironolactone, a potassium-sparing diuretic and aldosterone antagonist, reduces fluid retention and provides cardioprotective effects through mineralocorticoid receptor antagonism. The combination targets complementary pathways in pulmonary hypertension pathophysiology.","oneSentence":"Ambrisentan blocks endothelin-1 receptors to reduce pulmonary vascular resistance, while spironolactone is a mineralocorticoid receptor antagonist that provides additional hemodynamic and anti-fibrotic benefits.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:59.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT02253394","phase":"PHASE4","title":"The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2015-09","conditions":"Pulmonary Arterial Hypertension","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Letairis plus Aldactone"],"phase":"marketed","status":"active","brandName":"Ambrisentan plus Spironolactone","genericName":"Ambrisentan plus Spironolactone","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ambrisentan blocks endothelin-1 receptors to reduce pulmonary vascular resistance, while spironolactone is a mineralocorticoid receptor antagonist that provides additional hemodynamic and anti-fibrotic benefits. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}